507 related articles for article (PubMed ID: 21055801)
1. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.
de Zeeuw D; Agarwal R; Amdahl M; Audhya P; Coyne D; Garimella T; Parving HH; Pritchett Y; Remuzzi G; Ritz E; Andress D
Lancet; 2010 Nov; 376(9752):1543-51. PubMed ID: 21055801
[TBL] [Abstract][Full Text] [Related]
2. Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.
Parvanova A; Trillini M; Podestà MA; Iliev IP; Ruggiero B; Abbate M; Perna A; Peraro F; Diadei O; Rubis N; Gaspari F; Carrara F; Stucchi N; Belviso A; Bossi AC; Trevisan R; Remuzzi G; de Borst M; Ruggenenti P;
Lancet Diabetes Endocrinol; 2018 Jan; 6(1):27-40. PubMed ID: 29104158
[TBL] [Abstract][Full Text] [Related]
3. Paricalcitol versus placebo for reduction of proteinuria in kidney transplant recipients: a double-blind, randomized controlled trial.
Oblak M; Mlinšek G; Kandus A; Buturović-Ponikvar J; Arnol M
Transpl Int; 2018 Dec; 31(12):1391-1404. PubMed ID: 30062716
[TBL] [Abstract][Full Text] [Related]
4. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.
de Zeeuw D; Bekker P; Henkel E; Hasslacher C; Gouni-Berthold I; Mehling H; Potarca A; Tesar V; Heerspink HJ; Schall TJ;
Lancet Diabetes Endocrinol; 2015 Sep; 3(9):687-96. PubMed ID: 26268910
[TBL] [Abstract][Full Text] [Related]
5. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
[TBL] [Abstract][Full Text] [Related]
6. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
[TBL] [Abstract][Full Text] [Related]
7. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
8. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.
de Zeeuw D; Renfurm RW; Bakris G; Rossing P; Perkovic V; Hou FF; Nangaku M; Sharma K; Heerspink HJL; Garcia-Hernandez A; Larsson TE
Lancet Diabetes Endocrinol; 2018 Dec; 6(12):925-933. PubMed ID: 30413396
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D receptor activation with calcitriol for reducing urinary angiotensinogen in patients with type 2 diabetic chronic kidney disease.
Tiryaki Ö; Usalan C; Sayiner ZA
Ren Fail; 2016; 38(2):222-7. PubMed ID: 26707134
[TBL] [Abstract][Full Text] [Related]
11. The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics.
Lambers Heerspink HJ; Agarwal R; Coyne DW; Parving HH; Ritz E; Remuzzi G; Audhya P; Amdahl MJ; Andress DL; de Zeeuw D
Am J Nephrol; 2009; 30(3):280-6. PubMed ID: 19521070
[TBL] [Abstract][Full Text] [Related]
12. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
[TBL] [Abstract][Full Text] [Related]
13. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.
Kohan DE; Pritchett Y; Molitch M; Wen S; Garimella T; Audhya P; Andress DL
J Am Soc Nephrol; 2011 Apr; 22(4):763-72. PubMed ID: 21372210
[TBL] [Abstract][Full Text] [Related]
14. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK
Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
[TBL] [Abstract][Full Text] [Related]
15. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Heerspink HJL; Parving HH; Andress DL; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Melnick JZ; Miller MG; Pergola PE; Perkovic V; Tobe S; Yi T; Wigderson M; de Zeeuw D;
Lancet; 2019 May; 393(10184):1937-1947. PubMed ID: 30995972
[TBL] [Abstract][Full Text] [Related]
16. Intervention using vitamin D for elevated urinary albumin in type 2 diabetes mellitus (IDEAL-2 Study): study protocol for a randomised controlled trial.
Taheri S; Asim M; Al Malki H; Fituri O; Suthanthiran M; August P;
Trials; 2018 Apr; 19(1):230. PubMed ID: 29665833
[TBL] [Abstract][Full Text] [Related]
17. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
Tofte N; Lindhardt M; Adamova K; Bakker SJL; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Heerspink HJL; Kooy A; Laverman GD; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Petrie JR; Ruggenenti PL; Rutters F; Rychlík I; Siwy J; Spasovski G; Speeckaert M; Trillini M; Zürbig P; von der Leyen H; Rossing P;
Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
[TBL] [Abstract][Full Text] [Related]
18. Effects of Vitamin D Receptor Activation and Dietary Sodium Restriction on Residual Albuminuria in CKD: The ViRTUE-CKD Trial.
Keyzer CA; van Breda GF; Vervloet MG; de Jong MA; Laverman GD; Hemmelder MH; Janssen WM; Lambers Heerspink HJ; Kwakernaak AJ; Bakker SJ; Navis G; de Borst MH;
J Am Soc Nephrol; 2017 Apr; 28(4):1296-1305. PubMed ID: 27856633
[TBL] [Abstract][Full Text] [Related]
19. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial.
Kwakernaak AJ; Krikken JA; Binnenmars SH; Visser FW; Hemmelder MH; Woittiez AJ; Groen H; Laverman GD; Navis G;
Lancet Diabetes Endocrinol; 2014 May; 2(5):385-95. PubMed ID: 24795252
[TBL] [Abstract][Full Text] [Related]
20. Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial.
Parvanova A; van der Meer IM; Iliev I; Perna A; Gaspari F; Trevisan R; Bossi A; Remuzzi G; Benigni A; Ruggenenti P;
Lancet Diabetes Endocrinol; 2013 Sep; 1(1):19-27. PubMed ID: 24622263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
